



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/08, 9/48, 9/66 A61K 47/14, 31/10	A1	(11) International Publication Number: WO 92/10996 (43) International Publication Date: 9 July 1992 (09.07.92)
(21) International Application Number: PCT/US91/08565 (22) International Filing Date: 15 November 1991 (15.11.91) (30) Priority data: 629,540 18 December 1990 (18.12.90) US (71) Applicant: MERRELL DOW PHARMACEUTICALS INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US). (72) Inventors: BASSLER, Kenneth, G. ; 303 John Street, Carmel, IN 46032 (US). DEEPAK, Phadke, S. ; 8827 Ginnylock Drive, Indianapolis, IN 46256 (US). NEDDERMEYER, Melissa, P. ; 5427 Ginnylock Drive, Indianapolis, IN 46255 (US).		(74) Agents: SAYLES, Michael, J. et al.; Marion Merrell Dow Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i> <div style="text-align: center; border: 1px solid black; border-radius: 50%; width: 100px; height: 100px; margin: 20px auto; display: flex; align-items: center; justify-content: center; font-size: 40px;">AJ</div>
(54) Title: ENHANCED BIOAVAILABILITY PHARMACEUTICAL COMPOSITION CONTAINING PROBUCOL (57) Abstract <p>A pharmaceutical composition of probucol that both enhances bioavailability of the drug and reduces plasma drug level variability in a patient population comprising a therapeutically effective amount of probucol dissolved in a propylene glycol ester of fatty acids wherein the fatty acids are selected from the group consisting of the fatty acids represented by $C_xH_{2x}O_2$, wherein x is 4, 6, 8, 10, 12, 14, 16.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

ENHANCED BIOAVAILABILITY PHARMACEUTICAL COMPOSITION CONTAINING PROBUCOLBACKGROUND OF THE INVENTION

5 Probucol, a serum cholesterol lowering agent, is presently marketed as Lorelco® 250 and 500 mg tablets. The bioavailability of probucol from tablet dosage form is estimated to be 2-8 percent [J.F. Heeg and H. Tachizawa, Nouv. Presse Med., 9, 2990-2994 (1980)]. This poor
10 bioavailability is most likely caused by the extremely hydrophobic nature of probucol. Several approaches for improving the bioavailability of poorly water soluble drugs have been reported in the literature. Drugs are absorbed from the gastrointestinal tract most rapidly when adminis-
15 tered as aqueous solutions. The absorption rate of a drug from an oil solution may be enhanced, however, if the oil is digestible. Therefore, it was considered appropriate to develop an oil solution formulation of probucol filled in a hard gelatin capsule as one of the approaches to improving
20 its bioavailability. In developing such a formulation, it was unexpectedly discovered that one such formulation that increased bioavailability also resulted in reduced variability of plasma drug levels of probucol in a patient population to which the formulation was administered.


25

SUMMARY OF THE INVENTION

Three new pharmaceutical dosage forms of probucol were prepared and the relative bioavailability was evaluated in man. One of these dosage form, a solution of probucol in Captex® 200 filled in hard gelatin capsules, was found (by extrapolation) to be approximately equal to the Lorelco® 500 tablet at about 1/6 the dose. The solubility of probucol was determined in several natural and derived vegetable oils. Captex® 200, a vegetable oil containing propylene glycol esters of caprylic (C₈) and capric (C₁₀) fatty acids, provided the highest solubility for probucol and was therefore selected as the preferred vehicle for an improved probucol formulation. Also, unexpectedly, there was significantly less variability in probucol plasma drug levels with the Captex® 200 formulation. In view of the increased bioavailability of probucol when administered in the Captex® 200 formulation and in light of the unexpected reduced variability in probucol plasma levels, this formulation is the subject of this application.

DETAILED DESCRIPTION OF THE INVENTION

Probucol is a compound according to Formula I, namely 2,2'-bis (3,5-di-tertiarybutyl-4-hydroxyphenylthio)propane.



FORMULA I

-3-

The compounds of Formula I can be prepared as described in U.S. Patents Nos. 3,576,883, 3,786,100, 3,862,332, 3,987,500 and 4,900,757, incorporated herein by reference. More specifically, 2,2'-bis (3,5-di-tertiarybutyl-4-hydroxy phenylthio)propane can be prepared as described in U.S.

- 5 Patent No. 3,576,883, also incorporated herein by reference. Alternately, this compound can be prepared according to the method set forth in U.S. Patent Nos. 4,734,527 (Kraus) or 4,861,443 (Van Effen), incorporated herein by reference. The indication for probucol is primary hypercholesterolemia.
- 10 Recent studies in animals have indicated that probucol has a beneficial effect on atherosclerosis independent of cholesterol lowering.

- The present invention is directed towards pharmaceutical
- 15 compositions of probucol dissolved in a propylene glycol ester of fatty acids wherein the fatty acids are selected from the group consisting of the fatty acids represented by $C_xH_{2x}O_2$, wherein x is 4, 6, 8, 10, 12, 14, 16. This group specifically includes butyric acid, caproic acid, caprylic
- 20 acid, capric acid, lauric acid, myristic acid and palmitic acid. The most preferred embodiment of the invention is a propylene glycol ester of capric and caprylic acids, known as propylene glycol dicaprylate/dicaprate. Captex® 200 is a specific trade name for propylene glycol dicaprylate/-
- 25 dicaprate and is supplied by Karlshamns Lipid Specialties USA, P.O. Box 569, Columbus, OH 43216-0569. Reference to Captex® 200 should not be construed as limiting and it will be understood that any reference to Captex® 200 should be construed to generically include all propylene glycol
- 30 dicaprylates/dicaprates. Propylene glycol dicaprylate/-dicaprate is also known as Neobee 20, supplied by Stepan Co., PVO Dept., 100 W. Hunter Ave., Maywood, NJ 07607, and as Miglyol 840, supplied by Huls America, P.O. Box 456, Piscataway, NJ 08855-0456. Captex® 300 and Capmul MCM is
- 35 also supplied by Karlshamns Lipid Specialties USA.

SOLUBILITY DETERMINATION

The solubility of probucol was determined in olive, sunflower, peanut, vegetable, corn, Captex® 200 and 300, and Capmul® MCM oils. Captex® 200 is a propylene glycol ester of caprylic (C₈) and capric (C₁₀) fatty acids obtained by fractionation of certain coconut oil fatty acids and is known generically as propylene glycol dicaprylate/dicaprate. Captex® 300 is a caprylic and capric acid triglyceride obtained by fractionation and subsequent esterification of coconut oil and is known generically as caprylic/capric triglyceride. Capmul® MCM is a mono and diglyceride of caprylic and capric acids.

Eight grams of each oil were transferred into a glass tube with a teflon liner screw cap, and 2.5 g of probucol were added to each tube. The tubes were capped and shaken by hand until the probucol particles were wetted. The tubes were then rotated for at least 48 hours on a test tube rotating apparatus. The solubility of probucol was determined using a high performance liquid chromatography (HPLC) assay procedure.

The solubility values (%w/v) of probucol in various oils are shown in Table I.

TABLE I
SOLUBILITY OF PROBUCOL IN VARIOUS OILS

<u>Oil</u>	<u>Solubility</u> <u>(% w/v)</u>	<u>Oil</u>	<u>Solubility</u> <u>(% w/v)</u>
Peanut	5.6	Corn	5.8
Olive	5.5	Captex® 200	18.2
Sunflower	5.8	Captex® 300	12.5
Safflower	5.9	Capmul® MCM	6.3
Vegetable	5.8		

The highest solubility was observed in Captex® 200 oil. Considering a 50 mg probucol dose, and the constraints on the capsule size and its fill volume, the Captex® 200 was selected for further study. Although coconut oil is known to increase the serum cholesterol level, the literature on Captex® oil indicated that the medium chain fatty acids present in this oil do not contribute to the increase in the cholesterol level. Additionally, there is also evidence that these acids are absorbed through the portal system [V.K. Babayan, Lipids, 22, 417-420 (1987)] and may actually lower the cholesterol level [J.W. Stewart, K.D. Wiggers, N.L. Jacobson, P.J. Berger, Journal of Nutrition, 108, 561-566 (1978) and D. Kritchevsky, S.A. Tepper, Journal of Nutrition, 86, 67-72 (1965)]. Although the exact mechanism of action of probucol is not completely understood, there is speculation that its primary mechanism of action is in the liver. The portal absorption of the fatty acids present in Captex® 200 may be an advantage if probucol is to exercise its action mainly in the liver.

20

In order to determine if the solubility of probucol could be enhanced by incorporating absolute ethanol in the oil, three binary systems: safflower oil:ethanol (90:10), polyethylene glycol (PEG) 400:ethanol (90:10, 80:20, 70:30), and Captex® 200:ethanol (95:5, 90:10, 85:15, 80:20, and 75:25) were evaluated. The solubility data shown in Table II indicate that in each case the solubility of probucol increased in the presence of ethanol.

30

35

TABLE II
SOLUBILITY OF PROBUCOL IN VARIOUS BINARY SOLVENT SYSTEMS

Solvent System	Ratio	Solubility (%w/v)
Safflower Oil:Ethanol	90:10	11.5
PEG 400	100:00	2.8
PEG 400:Ethanol	90:10	5.8
PEG 400:Ethanol	80:20	9.5
PEG 400:Ethanol	70:30	13.1
Captex® 200:Ethanol	95:5	23.0
Captex® 200:Ethanol	90:10	24.0
Captex® 200:Ethanol	85:15	25.0
Captex® 200:Ethanol	80:20	26.0
Captex® 200:Ethanol	75:25	26.0

13

BIOAVAILABILITY AND SERUM VARIABILITY STUDIES

Further studies were conducted to assess the bioavailability of the experimental formulations of probucol. Two studies were conducted as open, randomized, parallel studies with twelve subjects per treatment group. Lorelco® 500 mg tablets were used as the reference formulation and compared with a Scherer soft gelatin capsule (Protocol A) and Captex® Oil Solution and PEG (polyethylene glycol) 8000 comelt (Protocol B), respectively, each containing 50 mg of probucol.

The current formulation of Lorelco® is 500 mg of probucol in admixture with corn starch, ethylcellulose, glycerine, hydroxypropyl cellulose, hydroxypropyl methylcellulose 2910, iron oxide, lactose, magnesium stearate, microcrystalline cellulose, polysorbate 80, talc and titanium dioxide. PEG 8000 comelt is a mixture of probucol and polyethylene glycol 8000 (PEG 8000 is known in the art). Size two gelatin capsules were filled with 100 mg

35

-7-

of the 50:50 probucol:PEG 8000 comelt, corresponding to a 50 mg dose of probucol. The Scherer soft gel is a mixture of fill weight 310 mg consisting of 50 mg probucol, 208 mg Captex® 200, 26 mg polysorbate 80 and 26 mg Imwitor 742 (caprylic/capric glycerides-HULS America).

5

Summary statistics (mean, standard deviation, and coefficient of variation) for dose corrected pharmacokinetic parameters are listed in Tables III and IV for Protocols B and A respectively.

10

TABLE III
PROTOCOL B - Summary Statistics For Dose
Corrected Pharmacokinetic Parameters
Mean \pm S.D., (C.V.), (N = 12)

<u>Dose Corrected</u> <u>Parameters</u>	<u>Lorelco®</u>	<u>Captex® Oil</u>	<u>PEG 8000</u>
AUC ₁₆₈ ($\mu\text{g}\cdot\text{hr ml}^{-1}$)	162 \pm 108 (67%)	919 \pm 127 (14%)	979 \pm 363 (37%)
C _{MAX} ($\mu\text{g/ml}$)	2.32 \pm 1.50 (65%)	13.5 \pm 2.72 (20%)	13.9 \pm 4.23 (30%)
T _{MAX} (hr)	20.0 \pm 7.24 (36%)	18.3 \pm 7.13 (39%)	20.0 \pm 7.43 (37%)

TABLE IV
PROTOCOL A - Summary Statistics For Dose
Corrected Pharmacokinetic Parameters
Mean \pm S.D., (C.V.), (N = 12)

<u>Dose Corrected</u> <u>Parameters</u>	<u>Lorelco®</u>	<u>Scherer soft</u> <u>gel</u>
AUC ₁₆₈ ($\mu\text{g}\cdot\text{hr ml}^{-1}$)	276 \pm 126 (47%)	1017 \pm 328 (32%)
C _{MAX} ($\mu\text{g/ml}$)	3.74 \pm 1.55 (41%)	14.2 \pm 3.49 (25%)
T _{MAX} (hr)	18.7 \pm 6.89 (37%)	19.5 \pm 7.14 (37%)

35

For Protocol B, based on the dose corrected mean AUC (area under the curve) and C_{max} (maximum concentration) values, both Captex® Oil solution and PEG 8000 comelt are estimated to be 5 times or more bioavailable than the
5 Lorelco® 500 mg tablet (Table III). T_{max} values are similar for all three formulations. To make a fair comparison of the variabilities of the test formulations (Captex® Oil Solution and PEG comelt), and the reference formulation (Lorelco® 500 mg tablet), AUC and C_{max} values for Captex® Oil
10 Solution and PEG 8000 comelt were multiplied by 1.76 and 1.65, respectively (these scale factors were used so that all formulations have the same AUC values). Based on the standard deviation of these extrapolated values (Table V) and the coefficient of variation of the raw values (Table
15 III), AUC values of Captex® Oil Solution are approximately 25 and 7 times less variable than the Lorelco® tablet and the PEG 8000 treatment, respectively, and C_{max} values of Captex® Oil Solution are approximately 9 and 2.3 times less variable than the Lorelco® tablet and PEG 8000 treatment,
20 respectively. The variability of PEG 8000 comelt is similar to the Lorelco® 500 mg tablet.

Similar procedures were also used for Protocol A. Based on the dose corrected values, the Scherer soft gel treatment
25 is estimated to be 3.7 times more bioavailable than the Lorelco® 500 mg tablet (Table IV). T_{max} values are similar for both formulations. The variability of Scherer soft gel treatment is similar to the Lorelco® 500 mg tablet (Table
V).

30

35

TABLE V
Comparison Of Variances With Matched AUC Values
Standard Deviation Of The Extrapolated Values (N=12)

PROTOCOL B			
Treatment*			
Parameter	Lorelco®	PEG 8000	Captex® Oil
AUC ₁₆₈ (µg·hr ml ⁻¹)	108.2	61.8	22.9
CMAX (µg/ml)	1.50	0.72	0.49
TMAX (hr)	7.20	7.10	7.40

PROTOCOL A			
Treatment*			
Parameter	Lorelco®	Scherer soft	
AUC ₁₆₈ (µg·hr ml ⁻¹)	125.7	86.9	
CMAX (µg/ml)	1.55	0.94	
TMAX (hr)	6.90	7.10	

*Treatments with a common bracket are not significantly different.

EXAMPLE I

Probucol (50.0 mg) was dissolved in propylene glycol esters of caprylic/capric fatty acids [Captex® 200, manufactured and supplied by Karlshamns Lipid Specialties USA, P.O. Box 569, Columbus, OH 43216-0569, as Captex® 200, (283.0 mg) and stirred until a clear solution was obtained. The resulting clear solution was filled into hard gelatin capsules (white opaque gelatin capsule size no. 1, 73 mg) so that each capsule contained an approximate weight of 333.0

-10-

mg of solution. The bulk solution was assayed for probucol before filling the capsule and the fill weight was adjusted according to the actual percent of probucol in the solution to provide a 50 mg dose of probucol. Using a capsule banding apparatus, a solution of gelatin (0.647 mg), polysorbate 80 (0.027 mg), and purified water (2.076 mg) was applied to seal the cap to the body of the capsule. The gelatin band was then allowed to harden.

10

15

20

25

30

35

WHAT IS CLAIMED IS:

1. A pharmaceutical composition of probucol adapted to enhance the bioavailability of probucol while reducing plasma probucol level variability in a patient population comprising a therapeutically effective amount of probucol dissolved in a propylene glycol ester of fatty acids wherein the fatty acids are selected from the group consisting of the fatty acids represented by $C_xH_{2x}O_2$, wherein x is 4, 6, 8, 10, 12, 14, 16.
2. A pharmaceutical composition according to claim 1 wherein the fatty acids are selected from the group consisting of the fatty acids represented by $C_xH_{2x}O_2$, wherein x is 6, 8, 10, 12.
3. A pharmaceutical composition according to claim 1 wherein the fatty acids are selected from the group consisting of capric and caprylic acids.
4. Use of a pharmaceutical composition according to any of claims 1-3 to lower serum cholesterol levels.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/08565

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁸		
According to International Patent Classification (IPC) or to both National Classification and IPC Int. Cl. 5 A 61 K 9/08 A 61 K 9/48 A 61 K 9/66 A 61 K 47/14 A 61 K 31/10		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int. Cl. 5	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	US,A,3862332 (J.W. BARNHART) 21 January 1975, see the claims 1,3,8,11-12; column 12; example 9; column 13, example 14; column 14, example 17 (cited in the application) ---	1,4
A	US,A,4902513 (J. CARVAIS) 20 February 1990, see the claims; column 4, example XVIII -----	1,4
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
22-01-1992	17. 02. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	Danielle van der Haas	

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9108565
SA 54190

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 06/02/92.
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 3862332	21-01-75	DE-A, B, C 1767443 FR-M- 8064 GB-A- 1168193 NL-A- 6806010	09-09-71 06-07-70 22-10-69 12-11-68
US-A- 4902513	20-02-90	None	

EPO FORM P0079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82